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ABSTRACT
Background: Fecal biomarkers, especially fecal calprotectin, 
are useful for predicting endoscopic activity in Crohn’s disease; 
however, the cut-off point remains unclear. The aim of this paper 
was to analyze whether faecal calprotectin and M2 pyruvate 
kinase are good tools for generating highly accurate scores for the 
prediction of the state of endoscopic activity and mucosal healing. 
Methods: The simple endoscopic score for Crohn’s disease 
and the Crohn’s disease activity index was calculated for 71 
patients diagnosed with Crohn’s. Fecal calprotectin and M2-PK 
were measured by the enzyme-linked immunosorbent assay test. 
Results: A fecal calprotectin cut-off concentration of ≥ 170 
µg/g (sensitivity 77.6%, specificity 95.5% and likelihood ratio 
+17.06) predicts a high probability of endoscopic activity, and a 
fecal calprotectin cut-off of ≤ 71 µg/g (sensitivity 95.9%, specificity 
52.3% and likelihood ratio -0.08) predicts a high probability of 
mucosal healing. Three clinical groups were identified according to 
the data obtained: endoscopic activity (calprotectin ≥ 170), mucosal 
healing (calprotectin ≤ 71) and uncertainty (71 > calprotectin < 
170), with significant differences in endoscopic values (F = 26.407, 
p < 0.01). Clinical activity or remission modified the probabilities of 
presenting endoscopic activity (100% vs 89%) or mucosal healing 
(75% vs 87%) in the diagnostic scores generated. M2-PK was 
insufficiently accurate to determine scores.
Conclusions: The highly accurate scores for fecal calprotectin 
provide a useful tool for interpreting the probabilities of presenting 
endoscopic activity or mucosal healing, and are valuable in the 
specific clinical context.
Key words: Fecal calprotectin. Predicting cut-offs. Endoscopic 
activity. Mucosal healing.
INTRODUCTION
The persistent inflammatory activity in Crohn’s dis-
ease (CD) does not produce characteristic symptoms and 
is associated with poor prognosis (1). The assessment of 
symptoms has not proved to be useful in accurately estab-
lishing endoscopic activity despite the availability of instru-
ments such as the Crohn’s disease activity index (CDAI) 
(2). Since the main aim of treatment is to achieve mucosal 
healing (3), we need to base clinical criteria on tests that 
provide us with accurate and objective data to show the 
resolution or persistence of inflammatory activity in CD (4).
Ileo-colonoscopy with a biopsy is considered to be the 
“gold standard” for assessing intestinal inflammation, yet it 
is costly, not widely available and can cause complications 
(4-6). Although a series of specific endoscopic indices have 
been developed, such as the Crohn’s Disease Endoscopic 
Index of Severity (CDEIS) and the Simple Endoscopic 
Score for Crohn’s Disease (SES-CD), which can classify 
degrees of activity and correlate to a considerable degree 
(7), they are difficult to calculate and interpret in daily 
medical practice, although the SES-CD is simpler and eas-
ier to use (8). Likewise, the cut-off point is still not clearly 
defined for mucosal healing although some recent studies 
have opted for SES-CD ≤ 2 (9,10). If we also consider that 
colonoscopy for monitoring inflammatory activity can be 
complicated, then it is appropriate to identify and devel-
op non-invasive biomarkers by producing evidence that 
shows that fecal biomarkers, in particular fecal calprotectin 
(FC), are a more accurate tool for predicting inflammato-
ry activity in CD than blood tests (4). Such biomarkers 
include M2 pyruvate kinase (M2-PK), an enzyme that is 
expressed by continually replicating cells, such as intesti-
nal mucus cells. This enzyme can be detected in feces by 
the enzyme-linked immunosorbent assay (ELISA) (11). 
Various studies have confirmed that M2-PK is useful for 
diagnosing inflammatory bowel disease (IBD) as opposed 
to irritable bowel syndrome (IBS), although not as accu-
rately as FC. M2-PK levels also correlate well with the 
extent of activity of the disease (12), although its specific-
ity is lower than that of FC for predicting remission (13). 
FC is a calcium and zinc fixative protein found in the 
cytoplasm of granulocytes that represents 60% of its cytoso-
lic proteins (14). Its presence in feces is directly proportional 
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to the migration of neutrophils to the intestinal tract (15). 
It is simple and inexpensive to measure using ELISA, and 
shows a strong direct correlation between FC values and 
CD activity as measured by clinical, endoscopic and even 
histological indices (5,16). It is highly accurate for estab-
lishing endoscopic activity and is considered to be the most 
accurate indirect parameter for mucosal healing (17,18). It 
is also useful for identifying patients in deep remission who 
have fewer probabilities of relapsing in the short term (19).
Along these lines, Lin et al. (20) published a meta-analysis 
on FC accuracy in order to detect endoscopic activity, and 
Mosli et al. (4) have recently published a meta-analysis on 
the accuracy of C-reactive protein, FC and fecal lactoferrin 
to detect endoscopic activity in IBD patients. Both studies 
observed considerable heterogeneity between the various 
tests due to a lack of diagnostic methodology standardization 
as there are so few studies evaluating endoscopic activity. 
The two studies proposed different cut-offs for FC: 50 µg/g 
(5,21), 100 µg/g (17,22,23), 250 µg/g (24,25) and 274 µg/g 
(26), with no agreement on the optimum cut-off level. 
Therefore, the clinical applicability of FC is limited as 
no consensus exists on the optimum cut-off point for estab-
lishing endoscopic activity. Obtaining statistical evidence 
of the various ranges of scores in order to accurately clas-
sify the state of “endoscopic activity” or “mucosal healing” 
would be an advance in aiding decision-making without 
the need to carry out additional tests. This in turn would 
help us to increase the efficiency of daily clinical practice, 
to better classify our patients and to provide a more per-
sonalized therapeutic treatment. 
The aim of this study was to analyze the usefulness of 
FC and fecal M2-PK in the generation of highly accurate 
scores for predicting endoscopic activity and mucosal heal-
ing in monitored CD patients.
METHODS 
Patients 
Seventy-one patients diagnosed with CD were selected. They 
underwent an ileo-colonoscopy at the Juan Ramón Jiménez hospital 
in Huelva (Spain) and passed through a prospective and consecutive 
selection process based on the following inclusion criteria: CD diag-
nosed according to clinical, radiological, endoscopic and histological 
criteria; aged over 16, and informed consent given that was specific 
to this study. Exclusion criteria were: severe infection or inflamma-
tory disease symptoms other than CD, extensive intestinal resections 
(total or subtotal colectomy), chronic consumption of non-steroidal 
anti-inflammatory medication, pregnancy, and upper gastrointestinal 
or extensive small bowel damage, all observed in a previous test. 
Design 
The patients diagnosed with CD included in the study were those 
who received a complete ileo-colonoscopy, which enabled us to 
gather data to calculate the SES-CD index. Firstly, the patients were 
interviewed and data was gathered to calculate the CDAI, and all 
patients were given three containers for collecting feces: one for FC, 
another for fecal M2-PK and the third one for microbiological tests 
(stool test, for parasites in feces and Clostridium difficile toxins); 
the samples were stored at -20 °C as a positive result in any of these 
microbiological tests was considered to be an exclusion factor. All 
the data were entered on a data gathering sheet specifically designed 
for the study and kept by the principal investigator. 
Clinical and endoscopic activity 
The CDAI was used to determine clinical activity by performing 
a quantitative assessment of its eight parameters. A CDAI score of 
< 150 was defined as remission; a CDAI of 150-220 was consid-
ered to be mild activity; between 221 and 450 was considered as 
moderate; and > 450, as severe (27,28). All the patients were given 
a full ileo-colonoscopy, and oral polyethylene glycol was used for 
bowel preparation. We studied the appearance of the mucosa and 
the presence of lesions in each colonic section and at the end of the 
ileum to calculate the SES-CD, which measures four parameters 
on a scale of 1 to 3 according to severity or extension (ulcers and 
their size, percentage of ulcerated surface, percentage of inflamed 
surface and stenosis) at five sections (rectum, left colon, trans-
verse colon, right colon and ileum). This gives us a score, with the 
patients classified according to the endoscopic activity. Endoscopic 
remission is considered as SES-CD ≤ 2; mild activity as SES-CD 
3-6; moderate activity between 7 and 15, and severe activity at 
SES-CD > 15 (29,30).
Determining the fecal biomarkers
All the patients submitted three containers of feces following 
ileo-colonoscopy, which were stored at -20 °C. These were later 
defrosted and the ELISA test was applied to measure FC (Calprest® 
Eurospital, Trieste, Italy) and M2-PK levels (Schebo® - Tumor 
M2-PKTM ELISA Stool, Giessen, Germany). Calprest® showed 
results ranging from 15.6 µg/g to 500 µg/g, but for those patients 
with > 500 µg/g we performed a dilution appropriate for the samples 
extracted, which resulted in a score of over 1,000 µg/g. Schebo® - 
Tumor M2-PKTM ELISA showed results ranging between 1.0 U/l 
and 20 U/l; samples which were > 20 U/l were diluted, as previously 
done with Calprest®, which resulted in scores above 40 U/l. 
Statistical analysis 
A descriptive study of the data recorded the mean age of the 
patient, gender distribution, years of disease evolution, and location 
and distribution by degrees of activity and treatment. CDAI showed 
a normal distribution, whereas the other variables did not. An ANO-
VA test, with its significance Fisher-Snedecor F-statistics test, was 
performed to evaluate homogeneity in the age variable, according to 
the SES-CD and CDAI groups. The non-parametric Mann-Whitney 
U test was used to compare the averages of the biomarker levels in 
the different groups of activity. An accuracy analysis was made by 
estimating the FC and M2-PK ROC curves with respect to the SES-
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CD. We used the Youden index to calculate both biomarkers cut-off 
points with greater accuracy to establish endoscopic activity, as well 
as values for sensitivity and specificity, and for predictive scores: 
positive and negative, global accuracy and likelihood ratios (LR). A 
cut-off with a specificity of > 90% and LR+ of ≥ 10 was thought to 
present strong evidence to support the diagnostic hypothesis (endo-
scopic activity), and a cut-off point with a sensitivity of > 90% and 
LR- of ≤ 0.1 would offer strong enough proof to reject the hypothesis 
(31,32). Finally, the Fagan nomogram was calculated to determine the 
probability of endoscopic activity or mucosal healing after obtaining 
the biomarker score. In all cases a p-value of p < 0.05 was regarded as 
statistically significant. The statistical analysis was carried out using 
the SPSS 21.0, MedCalc 13.3.3 program and Excel 2013.
Ethical aspects
This study was approved by the ethics committee of the Hospital 
Juan Ramón Jiménez. All the patients who participated in the study 
signed a specific informed consent form.
RESULTS
The descriptive statistics of the patients is shown in 
table I. There were no significant differences regarding the 
age of the subjects in the SES-CD (F = 2.103, p = 0.108) 
or CDAI (F = 1.945, p = 0.131) groups. 
Levels of FC and fecal M2-PK according to activity 
Median FC levels were 71 µg/g for remission endoscopy, 
196 µg/g for mild activity, 383 µg/g for moderate activity, 
and 575 µg/g for severe activity. Median fecal M2-PK lev-
els were 2.4 U/l for remission endoscopy, 9.3 U/l for mild 
activity, 19.0 U/l for moderate activity and 22.2 U/l for 
severe activity. There were significant differences between 
some of the CDAI and SES-CD groups for FC (χ2
CDAI
 = 
25.442, p < 0.001; χ2
SES-CD
 = 39.817, p < 0.001) and M2-PK 
(χ2
CDAI
 = 7.940, p = 0.047; χ2
SES-CD
 = 24.709, p < 0.001). In 
particular, we observed that the CDAI index only showed 
significant differences for M2-PK in the remission and 
moderate groups (U
M-W
 = 177.5, p = 0.010); and for FC 
in the remission and mild groups (U
M-W
 = 124, p = 0.001), 
and remission and moderate groups (U
M-W 
= 83 p < 0.001). 
With regard to the SES-CD index, the only statistically 
significant differences for M2-PK were found between the 
remission group and the remaining groups (mild U
M-W 
= 
76, p = 0.005; moderate U
M-W 
= 66.5 p < 0.001; and severe 
U
M-W 
= 23, p = 0.001), but not between mild and moderate, 
and moderate and severe groups. Regarding FC, the only 
significant differences were found between the moderate 
and severe groups. Limiting the groups to remission or 
activity, we observed that there are differences in both 
biomarkers both for CDAI (calprotectin U
M-W 
= 207, p < 
0.001, M2-PK U
M-W 
= 406.5, p = 0.013) and SES-CD (cal-
Table I. Patient descriptive and frequency characteristics
Number of patients 71
Age (years); median (range) 41.5 (16-69)
Female gender 38 (53.52%)
Disease duration (years); median (range) 5.6 (0-41)
Disease location  
 Ileal 23 (32.4%) SES-CDc (median, RIQd) 6 (2-12)
 Colonic 17 (23.9%) Mucosal healing (≤ 2) 22 (31%)
 Ileocolonic 31 (43.7%) Mild activity (3-6) 15 (21.1%)
Disease phenotype  Moderate activity (7-15) 26 (36.6%)
 Stricturing 6 (8.5%) Severe activity (≥ 16) 8 (11.3%)
 Penetrating 2 (2.8%) CDAIe (median, RIQ) 164 (76-259)
 Non-str., non-p. 63 (88.7%) Remission (< 150) 31 (43.7%)
Medication at endoscopy  Mild activity (150-220) 20 (28.2%)
 5-ASAa 30 (42.2%) Moderate activity (221-450) 19 (26.8%)
 Corticosteroids 11 (15.5%) Severe activity (> 450) 1 (1.4%)
  Thiopurines 20 (28.1%) Calprotectin (µg/g); median (RIQd) 196 (96-419)
Methotrexate 2 (2.8%) M2-PKf (U/l); median (RIQ) 9.4 (2.5-21.8)
 Anti-TNFαa 10 (14.0%)
 No medication 10 (14.0%)
aAmninosalicylic acid; bTumor necrosis factor; cSimple Endoscopic Score for Crohn’s Disease; dInterquartile range; eCrohn’s disease activity index; fM2-piruvate kinase. 
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protectin U
M-W 
= 116.5, p < 0.001, M2-PK U
M-W 
= 217.5, 
p < 0.001). 
The interaction study of the localization and the endo-
scopic activity by the ANCOVA test showed no significant 
interaction effects in FC (F = .367, p = .695), but there 
were significant differences in the endoscopic activity (F = 
20.338, p < .001). Similarly, there was no significant inter-
action in FC (F = 1.089, p = 0.343), only in the endoscopic 
activity (F = 14.643, p < 0.001).
In addition, to test the probability of activity vs non activity 
groups, binary logistic regression modelling was performed. 
Our results showed that we can obtain the probability of hav-
ing endoscopic activity via a binary logistic equation using 
the levels of FC (p = 0.007) and CDAI (p = 0.006).
Accuracy of FC and fecal M2-PK to predict 
endoscopic activity (SES-CD > 2)
When considering the SES-CD classification, we 
observed that both M2-PK and FC present an area under 
the curve (the probability of correctly classifying a pair of 
individuals selected at random, as healthy and unhealthy/
positive or negative) to suggest that both biomarkers have 
a high degree of accuracy for predicting endoscopic activ-
ity (AUC
FC
 = 0.917, p < 0.001; AUC
M2-PK
 = 0.846, p < 
0.001). No significant differences between the ROC curves 
were found (Z = 1.751, p = 0.079).
Optimum FC scores for establishing inflammatory 
activity and mucosal healing 
The best biomarker for differentiating the SES-CD 
groups is FC. And it was also the only variable that had 
levels of sensitivity, specificity, LR+ and LR- required to 
provide accurate scores for predicting mucosal healing and 
endoscopic activity. 
The optimum FC cut-off point was calculated as 170 
µg/g for predicting a high probability of endoscopic activ-
ity (sensitivity 77.6%, specificity 95.5%, LR+ 17.06, LR- 
0.24 and global accuracy 83%; Youden index = 0.730). 
To establish a second group with a high probability of 
mucosal healing, we extracted an FC cut-off of 71 µg/g 
(sensitivity 95.9%, specificity 52.3%, LR+ 1.99, LR- 0.08, 
and global accuracy 80%). Three groups were thus defined: 
endoscopic activity (FC ≥ 170), mucosal healing (FC ≤ 
71), and uncertainty (71 > FC < 170). We observed signif-
icant differences in the endoscopic scores (F = 26.407, p < 
0.01), as well as an acceptable consistency with the CDAI 
index (τ
b
 = 0.420, p < 0.01).
The prevalence of endoscopic activity in our sample 
was 69% (pre-test probability). The Fagan nomogram cal-
culation yielded a 97% (IC 95%: 85-100%) post-test prob-
ability of presenting endoscopic activity for FC ≥ 170 µg/g, 
and only a 34% probability (IC 95%: 24-47%) for a level 
of < 170 µg/g. The prevalence of mucosal healing in our 
sample was 31%. The post-test probability of presenting 
mucosal healing for a subject with FC ≤ 71 µg/g was 84% 
(IC 95%: 57-96%), and if the subject presented FC > 71 
µg/g it was only 19% (IC 95%: 13-26%).
In the clinical activity group, the prevalence of endo-
scopic activity was 85%, and 48% for the clinical remission 
group. For those patients with FC ≥ 170 µg/g and clinical 
activity, the probability of having endoscopic activity was 
100%; however, if the subjects presented clinical remis-
sion, the probabilities fell to 89%. Likewise, the probabil-
ity of a subject presenting mucosal healing with FC ≤ 71 
µg/g was 87% if the subject presented clinical remission, 
and the probability would drop to 75% if this fell within 
clinical activity (Fig. 1). 
Fig. 1. Fagan plots. A. Probability of endoscopic activity for calprotectin 
cut-off ≥ 170 µg/g. B. Probability of mucosal healing for FC cut-off ≤ 
70 µg/g. C. Probability of endoscopic activity for FC cut-off ≥ 170 µg/g 
patients with clinical activity. D. Probability of mucosal healing for FC 
cut-off ≤ 70 µg/g patients with clinical activity. E. Probability of endo-
scopic activity for FC cut-off ≥ 170 µg/g patients with clinical remission. 
F. Probability of mucosal healing for FC cut-off ≤ 70 µg/g patients with 
clinical remission.
DISCUSSION 
FC had a diagnostic accuracy level for establishing 
endoscopic activity similar to that of other researchers (4). 
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Our optimum cut-off point of 170 µg/g reached a high 
level of specificity (95.5%) and a good rate of sensitivity 
(77.6%), similar to that achieved by Lobatón et al. (26). 
The Youden index for FC was higher than those recorded 
by Bjorkesten et al. (22) and Sipponen et al. (17), but sim-
ilar to Shastri et al. (13) and Schoepfer et al. (5). Currently 
there is no consensus on the optimum FC cut-off point 
for establishing the presence of inflammatory activity or 
mucosal healing in patients with Crohn’s disease; scores 
range from 50 µg/g and 272 µg/g (5,17,21-26,33).
As noted above, there are no significant differences 
between colonic and ilecolic in FC levels according to the 
endoscopic activity. It is reasonable to assume that a patient 
with mucosal healing must have remarkably low levels of 
FC, regardless of the location; similarly, patients having a 
larger affected area should have higher levels of FC.
The lack of consensus on fixed single cut-off limits the 
clinical applicability. If we lower the threshold for estab-
lishing activity or remission, we increase test sensitivity 
but diminish specificity, thus generating fewer false neg-
atives but more false positives. However, if we raise the 
cut-off, we get fewer false positives but more false nega-
tives; in other words, there will be lower probabilities of 
accurately classifying all patients with endoscopic activity. 
Consequently, we calculated two cut-off points that 
enable us to generate highly accurate scores in order to 
establish mucosal healing and inflammatory activity, by 
producing a central low accuracy zone, or uncertainty 
zone, to establish the presence of endoscopic activity. We 
have calculated high precision scores by identifying the 
confirmation threshold of endoscopic activity with a spec-
ificity value of > 90% and LR+ ≥ 10, and a threshold for 
the exclusion of endoscopic activity at a sensitivity value 
of > 90% and LR- ≤ 0.1 (31,32). Real clinical usefulness 
is determined by the extent to which the FC enables us to 
step out of the area between the two thresholds (the “uncer-
tainty zone”), which will depend on the LR value and the 
initial pre-test probability (prevalence). 
FC presented the diagnostic accuracy levels necessary 
for generating highly accurate scores while M2-PK did not 
reach the required levels for LR+ or LR-. The most precise 
cut-off point for establishing endoscopic activity was FC 
≥ 170 µg/g (specificity = 95.5% and LR+ = 17.24), with 
FC ≤ 71 µg/g (sensibility = 95.9% and LR- = 0.08) as the 
most accurate cut-off for establishing mucosal healing. Our 
sample fixed the “uncertainty zone” of FC levels between 
72 µg/g and 169 µg/g. Either side of this interval, with 
an FC ≥ 170 µg/g the probability of finding subjects with 
inflammatory activity is 17 times greater than with a lower 
FC; and with an FC ≤ 71 µg/g the probability of finding 
subjects without endoscopic activity, and hence mucosal 
healing, is 12 times greater. 
The Fagan nomogram helps us to classify the patient 
probabilities as percentages, and thus enables an even 
better clinical applicability. In our sample, the prevalence 
of endoscopic activity was 69%, but if a patient has an 
FC ≥ 170 µg/g they have a 97% probability of presenting 
endoscopic activity; and if they had an FC ≤ 71 µg/g, the 
probability would be 84% for presenting mucosal healing. 
In both cases, the accuracy would be sufficiently good to 
establish, firstly, endoscopic activity, and then, mucosal 
healing, which would allow us to make decisions without 
the need to perform a colonoscopy. 
These scores are in line with the CDAI, which sup-
ports Mosli et al. (4) in their findings that FC is a useful 
biomarker for determining the presence of endoscopic 
activity, but the score should always be interpreted on an 
individual basis according to the specific clinical context. 
Endoscopic activity is more prevalent in patients with clin-
ical symptoms than in those in clinical remission, and we 
should take this into account when interpreting the prob-
abilities of presenting endoscopic activity after obtaining 
the FC score. In our sample, the prevalence of endoscopic 
activity was greater in patients with clinical activity (85%) 
than in those with clinical remission (48%). This implies 
variations in the probabilities of presenting activity with 
fecal FC ≥ 170 µg/g (100% vs 89%). Likewise, the proba-
bilities of predicting the state of mucosal healing if FC is 
≤ 71 µg/g would be 87% if presenting clinical remission, 
and 75% with clinical activity. 
Those patients with subclinical inflammatory activity will 
have a worse evolution with a strong probability of a new 
relapse (34,35) or even complications that may require sur-
gery (36). FC would be an ideal test to identify the presence of 
inflammatory activity in asymptomatic patients, enabling us 
to monitor the evolution of this activity and response to treat-
ment. There is a high correlation between FC levels and the 
lesions in the small intestine observed by magnetic resonance 
enterography in patients with CD (37) or capsule endoscopy 
in patients suspected of EC and not yet diagnosed (38). 
Combining clinical activity and FC could help us to 
make a series of highly accurate diagnostic and therapeutic 
decisions. The results and conclusions obtained may be 
useful in the efficient management of patients with CD in 
clinical practice, and used to prepare a decision diagram 
(Fig. 2), which incorporates the significant variables in our 
binary logistic regression model (CDAI and FC). 
In this regard, when a patient with EC comes to our 
clinic, we should first check whether they are in remission 
or clinical activity. Then the use of the CDAI as a screening 
tool would be necessary. Once the subjects have been clas-
sified as in remission or activity, the values of the FC will 
determine how to act. Thus, we can divide the subjects into 
three ranges: ≤ 71 mg/g, 72-169 mg/g, and ≥ 170 mg/g, 
depending on whether the subjects are in “clinical activity” 
or “remission”, which will aid us in how to proceed.
Patients who are in the area of uncertainty (72-169 mg/g) 
represented 28% of the total sample population. These 
patients, in spite of knowing their clinical activity and lev-
el of fecal calprotectin, have a low accuracy to establish 
the presence or activity of endoscopic mucosal healing. If 
these patients have symptoms they should undergo further 
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tests (colonoscopy and/or magnetic enteroresonance imag-
ing) to detect presence or absence of infl ammatory activity. 
If patients are asymptomatic, they would be candidates for 
monitoring fecal calprotectin in the coming months and, 
if the level increases above 170 mg/g, intensify treatment; 
otherwise, if they present symptoms, they should undergo 
another test to detect the presence of infl ammatory activity 
and modify the treatment.
We recognize that our sample is highly localized, so 
the study would improve substantially if it included more 
subjects from a variety of locations. Secondly, we have 
analyzed infl ammatory activity using only ileo-colonosco-
py, hence we have taken no data for activity in segments 
of the small intestine other than the ileum, nor from the 
upper gastrointestinal tract. Finally, this is a cross-sectional 
study, so there is no monitoring of FC levels, which would 
be useful for evaluating the evolution of patients according 
to their activity and assessing the response to changes in 
treatment in a longitudinal study. 
Although it is important to take into account the specifi c 
clinical context in order to interpret the probabilities of pre-
senting endoscopic activity and mucosal healing according 
to the FC level, this study shows that FC is a useful tool for 
generating highly accurate scores for predicting the state 
of endoscopic activity and mucosal healing in CD patients. 
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